Charting New Territories in Kinase Drug Discovery

   Confluence Life Sciences, Inc. is a technology-based company focusing on rational drug design to identify proprietary, mechanistically novel drugs. Founded by R&D leaders and world-class kinase experts, Confluence is an innovator in the discovery and development of breakthrough medicines for the treatment of cancer and autoimmune/ inflammatory diseases.  The team focuses on the design and development of kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis, or in reduction of chronic inflammation. Confluence utilizes a detailed structural and functional understanding of kinase enzymes and its proprietary KINect™ Technology Platform to design proprietary inhibitors in a fraction of the time of traditional approaches.